Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ofloxacin
Drug ID BADD_D01598
Description A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Indications and Usage For the treatment of infections (respiratory tract, kidney, skin, soft tissue, UTI), urethral and cervical gonorrhoea.
Marketing Status approved
ATC Code J01MA01; S01AE01; S02AA16
DrugBank ID DB01165
KEGG ID D00453
MeSH ID D015242
PubChem ID 4583
TTD Drug ID D03NHW
NDC Product Code 13985-602; 17478-713; 24208-410; 60505-0560; 63187-472; 63187-734; 0404-7189; 68071-2265; 68788-8195; 70756-607; 75834-119; 11980-779; 53002-1604; 53002-2604; 50090-5186; 60505-0363; 70518-2037; 71209-099; 70518-0192; 70518-3573; 59116-1820; 68788-8178; 70518-3710; 71205-420; 53069-0440; 53002-1324; 63187-184; 64980-432; 71209-097; 58032-0090; 24208-434; 68071-2254; 68071-2544; 68071-2834; 75834-112; 75834-120; 68071-3448; 68788-7693; 72189-108; 50090-1346; 63187-662; 64980-515; 63187-268; 63629-8716; 68788-8264; 68788-8449; 71209-098; 59390-140
UNII A4P49JAZ9H
Synonyms Ofloxacin | Ofloxacine | Tarivid | ORF-28489 | ORF 28489 | ORF28489 | DR-3355 | DR 3355 | DR3355 | Hoe-280 | Hoe 280 | Hoe280 | Ofloxacin Hydrochloride | Ru-43280 | Ru 43280 | Ru43280 | DL-8280 | DL 8280 | DL8280
Chemical Information
Molecular Formula C18H20FN3O4
CAS Registry Number 82419-36-1
SMILES CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001---
Abdominal pain07.01.05.002--
Acidosis14.01.03.002--
Acute hepatic failure09.01.03.0010.000125%-
Aggression19.05.01.001---
Agitation17.02.05.012; 19.06.02.001--
Agranulocytosis01.02.03.0010.000083%-
Albuminuria20.02.01.001---
Anaemia01.03.02.001--
Anaphylactic reaction10.01.07.001; 24.06.03.0060.000167%
Anaphylactic shock10.01.07.002; 24.06.02.004---
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.0010.000208%-
Anuria20.01.03.002---
Anxiety19.06.02.0020.000417%
Apathy19.04.04.0020.000208%-
Aphasia17.02.03.001; 19.21.01.001--
Application site pruritus08.02.01.005; 12.07.01.005; 23.03.12.004---
Application site reaction08.02.01.006; 12.07.01.006---
Arthralgia15.01.02.0010.000333%
Ascites02.05.04.002; 07.07.01.001; 09.01.05.003--
Asthenia08.01.01.0010.000208%-
Ataxia08.01.02.004; 17.02.02.001--
Atrial fibrillation02.03.03.0020.000125%
Blister12.01.06.002; 23.03.01.0010.000125%-
Blood creatinine increased13.13.01.004--
Blood urea increased13.13.01.006---
Body temperature increased13.15.01.001---
Breath odour07.01.06.002---
Bronchospasm10.01.03.012; 22.03.01.004--
Cardiac arrest02.03.04.0010.000125%
The 1th Page    1 2 3 4 5    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene